ci 934 has been researched along with imipenem, anhydrous in 1 studies
| Studies (ci 934) | Trials (ci 934) | Recent Studies (post-2010) (ci 934) | Studies (imipenem, anhydrous) | Trials (imipenem, anhydrous) | Recent Studies (post-2010) (imipenem, anhydrous) |
|---|---|---|---|---|---|
| 33 | 0 | 2 | 4,784 | 391 | 1,397 |
| Protein | Taxonomy | ci 934 (IC50) | imipenem, anhydrous (IC50) |
|---|---|---|---|
| Beta-lactamase | Pseudomonas aeruginosa | 0.15 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gottschall, S; Kim, MJ; Randall, EL; Weiser, M | 1 |
1 other study(ies) available for ci 934 and imipenem, anhydrous
| Article | Year |
|---|---|
Identification of Streptococcus faecalis and Streptococcus faecium and susceptibility studies with newly developed antimicrobial agents.
Topics: Ampicillin; Anti-Bacterial Agents; Ciprofloxacin; Enterococcus faecalis; Erythromycin; Fluoroquinolones; Humans; Imipenem; Microbial Sensitivity Tests; Quinolines; Streptococcus; Thienamycins; Vancomycin | 1987 |